- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:obesity [02.07.2019] – [Evidence of infectious cause] sallieq | home:diseases:obesity [02.08.2019] – [Research] sallieq | ||
|---|---|---|---|
| Line 29: | Line 29: | ||
| Restoration of the gastrointestinal mucosal barrier may include dietary changes, treatment of dysbiosis, digestive supports, and anti-inflammatory therapies. | Restoration of the gastrointestinal mucosal barrier may include dietary changes, treatment of dysbiosis, digestive supports, and anti-inflammatory therapies. | ||
| {{: | {{: | ||
| + | |||
| + | |||
| Line 103: | Line 105: | ||
| - | |||
| - | |||
| - | ==== Recent research ==== | ||
| - | |||
| - | Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. | ||
| Line 124: | Line 121: | ||
| Pediatrics, Sept. 2010 | Pediatrics, Sept. 2010 | ||
| - | see also Fecal microbiota composition in children may predict overweight.(({{pubmed> | + | see also {{http:// |
| + | |||
| + | |||
| + | |||
| + | Fecal microbiota composition in children may predict overweight.(({{pubmed> | ||
| ===== Learn More ===== | ===== Learn More ===== | ||
home/diseases/obesity.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.